Partial Retraction of Correspondence about "The pentapeptide QYNAD does not block voltage-gated sodium channels"

Heinrich Brinkmeier, PhD, Frank Weber, MD, Peter Aulkemeyer, PhD, Kurt H. Wollinsky, MD, Reinhardt Rüdel, PhD, Ulm and Greifswald, Germany; published as Correspondence in Neurology 2003;60:1871–1872

Note from the Scientific Integrity Advisor and Editor-in-Chief:

We learned from one of the authors of the above Correspondence, Reinhardt Rüdel, PhD, and the President of the University of Ulm, Professor Dr. K.J. Ebeling, that co-author Peter Aulkemeyer, PhD, committed scientific fraud. The following sentence from the Correspondence was based upon his fraudulent experimentation and is hereby retracted: "We have now installed the more sensitive ion trap technique for mass detection and quantification and find QYNAD and pyQYNAD in CSF samples of all assessed MS and of GBS patients, but not of controls."

Robert B. Daroff, MD
Scientific Integrity Advisor, *Neurology*

Robert C. Griggs, MD
Editor-in-Chief, *Neurology*

Partial Retraction of Correspondence about "The pentapeptide QYNAD does not block voltage-gated sodium channels"

Heinrich Brinkmeier, Frank Weber, Peter Aulkemeyer, et al.

Neurology 2006;66;456
DOI 10.1212/01.wnl.0000199280.83686.54